What the dental practitioner needs to know about pharmaco-therapeutic modalities of COVID-19 treatment: A review

Dar‐Odeh, Najla; Elsayed, Shadia A.; Babkair, Hamzah; Abu‐Hammad, Shaden; Althagafi, Nebras; Bahabri, Rayan; Eldeen, Yasmin Salah; Al-Johani, Wejdan Ali; Abu‐Hammad, Osama

doi:10.1016/j.jds.2020.11.007

Cited by 13 publications

(13 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Paracetamol and ibuprofen are repurposed and are regarded as supportive therapeutic option for COVID-19 patients [ 78 , 79 ]. Early administration of ibuprofen might prevent some complications of COVID-19 [ 80 ], and a recent study found that acute or chronic use was not concomitant with COVID-19 outcomes [ 81 ].…”

Section: Drug-induced Hepatic Injury In Covid-19mentioning

confidence: 99%

Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis

et al. 2021

View full text Add to dashboard Cite

Globally, millions of persons have contracted the coronavirus disease 2019 (COVID-19) over the past several months, resulting in significant mortality. Health care systems are negatively impacted including the care of individuals with cancers and other chronic diseases such as chronic active hepatitis, cirrhosis and hepatocellular carcinoma. There are various probable pathogenic mechanisms that have been presented to account for liver injury in COVID-19 patients such as hepatotoxicity cause by therapeutic drugs, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of the bile duct cells and hepatocytes, hypoxia and systemic inflammatory response. Liver biochemistry tests such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) are deranged in COVID-19 patients with liver injury. Hepatocellular damage results in the elevation of serum AST and ALT levels in early onset disease while a cholestatic pattern that develops as the disease progress causes higher levels of ALP, GGT, direct and total bilirubin. These liver biochemistry tests are prognostic markers of disease severity and should be carefully monitored in COVID-19 patients. We conducted a systematic review of abnormal liver biochemistry tests in COVID-19 and the possible pathogenesis involved. Significant findings regarding the severity, hepatocellular pattern, incidence and related clinical outcomes in COVID-19 patients are highlighted.

show abstract

Section: Drug-induced Hepatic Injury In Covid-19mentioning

confidence: 99%

Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Paracetamol and ibuprofen are repurposed and are regarded as supportive therapeutic option for COVID-19 patients [104,105]. Early administration of ibuprofen might prevent some complications of COVID-19 [106], and a recent study found that acute or chronic use was not concomitant with COVID-19 outcomes [107].…”

Section: Paracetamol and Acetaminophenmentioning

confidence: 99%

Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis

McGrowder

Miller

Cross

et al. 2021

Preprint

View full text Add to dashboard Cite

Globally, over the past several months millions of persons contracted the coronavirus disease 2019 (COVID-19) resulting in significant mortality. Health care systems are negatively impacted including the care of individuals with cancers and other chronic diseases such as chronic active hepatitis, cirrhosis and hepatocellular carcinoma. There are various probable pathogenic mechanisms that have been presented to account for liver injury in COVID-19 patients such as hepatotoxicity cause by therapeutic drugs, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of the bile duct cells and hepatocytes, hypoxia and systemic inflammatory response. Liver biochemistry tests such as AST, ALT, GGT and ALP are deranged in COVID-19 patients with liver injury. Hepatocellular damage results in the elevation of serum AST and ALT levels in early onset disease while a cholestatic pattern that develops as the disease progress causes higher levels of ALP, GGT, direct and total bilirubin. These liver biochemistry tests are prognostic markers of disease severity and should be carefully monitored in COVID-19 patients. We conducted a systematic review of abnormal liver biochemistry tests in COVID-19 and the possible pathogenesis involved. Significant findings regarding the severity, hepatocellular pattern, incidence and related clinical outcomes in COVID-19 patients are highlighted.

show abstract

“…The global pandemic coronavirus disease 2019 (COVID- 19) is the most challenging condition humanity has encountered in the twenty-first century [1], [2]. This pandemic has an impact on every sector of our life, particularly due to a lack of knowledge about the virus's route of transmission and how to treat and prevent it [2], [3]. Every society was negatively affected by the pandemic's psycho-emotional consequences.…”

Section: Introductionmentioning

confidence: 99%

Sleep Quality among Nurses during the First Year of Coronavirus Disease 2019

Alharbi

Mahrus

Elsayed

et al. 2021

Open Access Maced J Med Sci

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Nurses represent the largest section of the health-care workforce, and lack of sleep has an adverse influence on them, particularly during pandemics such as coronavirus disease 2019 (COVID-19). It causes not only health problem but also poor work results and an increased risk of medical errors. AIM: The goal of the study was to determine the prevalence of poor sleep quality among nurses during COVID-19 outbreaks. MATERIALS AND METHODS: A cross-sectional analysis was conducted among a group of nurses in the Al-Madinah region of Saudi Arabia at the National Guard Health Affairs in 2020 (1st year of the COVID-19 crisis). Data were collected using a validated questionnaire with two sections: Sociodemographic data such as age, nationality, family status, gender, and the Pittsburgh Sleep Quality Index. RESULTS: There were 238 nurses in the report. 37.8% of them were found to be between the ages of 31 and 35, while 24.4% were under the age of 30. The nurses were mostly female (84%). Sleep latency, sleep disruption, overall subjective sleep quality, and sleep length were the most widely identified sleep problems. Sixty-six percent of the nurses said they had a poor night’s sleep. None of the demographic variables analyzed had a significant relationship with overall sleep quality. CONCLUSION: Majority of nurses working at the National Guard Health Affairs and primary health-care centers in Al-Medina, Saudi Arabia, experience poor sleep quality, during the 1st year of COVID-19 crisis regardless of their demographic characteristics.

show abstract

What the dental practitioner needs to know about pharmaco-therapeutic modalities of COVID-19 treatment: A review

Cited by 13 publications

References 89 publications

Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis

Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis

Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis

Sleep Quality among Nurses during the First Year of Coronavirus Disease 2019

Contact Info

Product

Resources

About